Characterisation of novel defective thiopurine S-methyltransferase allelic variants

Biochemical Pharmacology

Volumn 76, Issue 3, 2008, Pages 404-415

  Garat, A ^a   Cauffiez, C ^a   Renault, N ^a   Lo Guidice, J M ^a   Allorge, D ^a   Chevalier, D ^a   Houdret, N ^a   Chavatte, P ^a   Loriot, M A ^b,c   Gala, J L ^d   Broly, F ^a  

^a UNIV LILLE   (France)

^b INSERM   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Heterologous expression; HPLC; Molecular modeling; Thiopurine drugs; TPMT genetic polymorphism

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

AMINO ACID SUBSTITUTION; ARTICLE; BLOOD TOXICITY; DNA FLANKING REGION; DRUG DETOXIFICATION; ENZYME ANALYSIS; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MISSENSE MUTATION; MOLECULAR MODEL; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; TPMT GENE;

EID: 46649107499     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.05.009     Document Type: Article

References (43)

1. Coulthard S., and Hogarth L. The thiopurines: an update. Invest New Drugs 23 (2005) 523-532
2. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 43 (1992) 329-339
3. Relling M.V., Hancock M.L., Rivera G.K., Sandlund J.T., Ribeiro R.C., Krynetski E.Y., et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 91 (1999) 1983-1985
4. Leeder J.S. Translating pharmacogenetics and pharmacogenomics into drug development for clinical pediatrics and beyond. Drug Discov Today 9 (2004) 567-573
5. Evans W.E., Hon Y.Y., Bomgaars L., Coutre S., Holdsworth M., Janco R., et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 19 (2001) 2293-2301
6. Weinshilboum R.M., and Sladek S.L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32 (1980) 651-662
7. Yates C.R., Krynetski E.Y., Loennechen T., Fessing M.Y., Tai H.L., Pui C.H., et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 126 (1997) 608-614
8. Schaeffeler E., Fischer C., Brockmeier D., Wernet D., Moerike K., Eichelbaum M., et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 14 (2004) 407-417
9. Schaeffeler E., Eichelbaum M., Reinisch W., Zanger U.M., and Schwab M. Three novel thiopurine S-methyltransferase allelic variants (TPMT*20, *21, *22)-association with decreased enzyme function. Hum Mutat 27 (2006) 976
10. Spire-Vayron de la Moureyre C., Debuysere H., Mastain B., Vinner E., Marez D., Lo Guidice J.M., et al. Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Br J Pharmacol 125 (1998) 879-887
11. Otterness D., Szumlanski C., Lennard L., Klemetsdal B., Aarbakke J., Park-Hah J.O., et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 62 (1997) 60-73
12. Heckmann J.M., Lambson E.M., Little F., and Owen E.P. Thiopurine methyltransferase (TPMT) heterozygosity and enzyme activity as predictive tests for the development of azathioprine-related adverse events. J Neurol Sci 231 (2005) 71-80
13. Gisbert J.P., Gomollón F., Cara C., Luna M., González-Lama Y., Pajares J.M., et al. Thiopurine methyltransferase activity in Spain: a study of 14,545 patients. Dig Dis Sci 52 (2007) 1262-1269
14. Spire-Vayron de la Moureyre C., Debuysère H., Fazio F., Sergent E., Bernard C., Sabbagh N., et al. Characterization of a variable number tandem repeat region in the thiopurine S-methyltransferase gene promoter. Pharmacogenetics 9 (1999) 189-198
15. Lee D., Szumlanski C., Houtman J., Honchel R., Rojas K., Overhauser J., et al. Thiopurine methyltransferase pharmacogenetics. Cloning of human liver cDNA and a processed pseudogene on human chromosome 18q21.1. Drug Metab Dispos 23 (1995) 398-405
16. Wu H., Horton J.R., Battaile K., Allali-Hassani A., Martin F., Zeng H., et al. Structural basis of allele variation of human thiopurine-S-methyltransferase. Proteins 67 (2007) 198-208
17. Jones G., Willett P., Glen R.C., Leach A.R., and Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267 (1997) 727-748
18. Clark M., Cramer III R.D., and Van Opdenbosch N. Validation of the general purpose Tripos 5.2 force field. J Comp Chem 10 (1989) 982-1012
19. Hamdan-Khalil R., Allorge D., Lo-Guidice J.M., Cauffiez C., Chevalier D., Spire C., et al. In vitro characterization of four novel non-functional variants of the thiopurine S-methyltransferase. Biochem Biophys Res Commun 309 (2003) 1005-1010
20. Gietz D., St Jean A., Woods R.A., and Schiestl R.H. Improved method for high efficiency transformation of intact yeast cells. Nucleic Acids Res 20 (1992) 1425
21. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 193 (1951) 265-275
22. Yan L., Zhang S., Eiff B., Szumlanski C.L., Powers M., O'Brien J.F., et al. Thiopurine methyltransferase polymorphic tandem repeat: genotype-phenotype correlation analysis. Clin Pharmacol Ther 68 (2000) 210-219
23. Anderson D.E., Becktel W.J., and Dahlquist F.W. pH-induced denaturation of proteins: a single salt bridge contributes 3-5 kcal/mol to the free energy of folding of T4 lysozyme. Biochemistry 29 (1990) 2403-2408
24. Covalt Jr. J.C., Roy M., and Jennings P.A. Core and surface mutations affect folding kinetics, stability and cooperativity in IL-1 beta: does alteration in buried water play a role?. J Mol Biol 307 (2001) 657-669
25. Krynetski E.Y., and Evans W.E. Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanisms and clinical importance. Pharmacology 61 (2000) 136-146
26. Tai H.L., Krynetski E.Y., Yates C.R., Loennechen T., Fessing M.Y., Krynetskaia N.F., et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 58 (1996) 694-702
27. Tai H.L., Krynetski E.Y., Schuetz E.G., Yanishevski Y., and Evans W.E. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci USA 94 (1997) 6444-6449
28. Pan H., Lee J.C., and Hilser V.J. Binding sites in Escherichia coli dihydrofolate reductase communicate by modulating the conformational ensemble. Proc Natl Acad Sci USA 97 (2000) 12020-12025
29. Bowie J.U., Reidhaar-Olson J.F., Lim W.A., and Sauer R.T. Deciphering the message in protein sequences: tolerance to amino acid substitutions. Science 247 (1990) 1306-1310
30. Lim W.A., Farruggio D.C., and Sauer R.T. Structural and energetic consequences of disruptive mutations in a protein core. Biochemistry 3 (1992) 4324-4333
31. Salavaggione O.E., Wang L., Wiepert M., Yee V.C., and Weinshilboum R.M. Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics. Pharmacogenet Genomics 15 (2005) 801-815
32. Tai H.L., Fessing M.Y., Bonten E.J., Yanishevsky Y., d'Azzo A., Krynetski E.Y., et al. Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C. Pharmacogenetics 9 (1999) 641-650
33. Sasaki T., Goto E., Konno Y., Hiratsuka M., and Mizugaki M. Three novel single nucleotide polymorphisms of the human thiopurine S-methyltransferase gene in Japanese individuals. Drug Metab Pharmacokinet 21 (2006) 332-336
34. Szumlanski C., Otterness D., Her C., Lee D., Brandriff B., Kelsell D., et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 15 (1996) 17-30
35. Spire-Vayron de la Moureyre C., Debuysère H., Sabbagh N., Marez D., Vinner E., Chevalier E.D., et al. Detection of known and new mutations in the thiopurine S-methyltransferase gene by single-strand conformation polymorphism analysis. Hum Mutat 12 (1998) 177-185
36. Hon Y.Y., Fessing M.Y., Pui C.H., Relling M.V., Krynetski E.Y., and Evans W.E. Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet 8 (1999) 371-376
37. Colombel J.F., Ferrari N., Debuysere H., Marteau P., Gendre J.P., Bonaz B., et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 118 (2000) 1025-1030
38. Hamdan-Khalil R., Gala J.L., Allorge D., Lo-Guidice J.M., Horsmans Y., Houdret N., et al. Identification and functional analysis of two rare allelic variants of the thiopurine S-methyltransferase gene, TPMT*16 and TPMT*19. Biochem Pharmacol 69 (2005) 525-529
39. Lindqvist M., Skoglund K., Karlgren A., Söderkvist P., Peterson C., Kidhall I., et al. Explaining TPMT genotype/phenotype discrepancy by haplotyping of TPMT*3A and identification of a novel sequence variant, TPMT*23. Pharmacogenet Genomics 17 (2007) 891-895
40. Krynetski E.Y., Schuetz J.D., Galpin A.J., Pui C.H., Relling M.V., and Evans W.E. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci USA 92 (1995) 949-953
41. Otterness D.M., Szumlanski C.L., Wood T.C., and Weinshilboum R.M. Human thiopurine methyltransferase pharmacogenetics. Kindred with a terminal exon splice junction mutation that results in loss of activity. J Clin Invest 101 (1998) 1036-1044
42. Schaeffeler E., Stanulla M., Greil J., Schrappe M., Eichelbaum M., Zanger U.M., et al. A novel TPMT missense mutation associated with TPMT deficiency in a 5-year-old boy with ALL. Leukemia 17 (2003) 1422-1424
43. Lindqvist M., Haglund S., Almer S., Peterson C., Taipalensu J., Hertervig E., et al. Identification of two novel sequence variants affecting thiopurine methyltransferase enzyme activity. Pharmacogenetics 14 (2004) 261-265